Cargando…

The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy

Diabetic kidney disease (DKD) is a chronic disorder characterized by elevated urine albumin excretion, reduced glomerular filtration rate, or both. At present, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are the standard care for the treatment of DKD, resulting in impro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matthews, Jennifer Rose, Schlaich, Markus P., Rakoczy, Elizabeth Piroska, Matthews, Vance Bruce, Herat, Lakshini Yasaswi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944990/ https://www.ncbi.nlm.nih.gov/pubmed/35327323 http://dx.doi.org/10.3390/biomedicines10030522

Ejemplares similares

SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes
por: Herat, Lakshini Yasaswi, et al.
Publicado: (2023)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)

Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy
por: Herat, Lakshini Y., et al.
Publicado: (2018)

Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
por: Herat, Lakshini Y., et al.
Publicado: (2022)

Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes
por: Matthews, Jennifer, et al.
Publicado: (2021)

The Sympathetic Nervous System Regulates Sodium Glucose Co-Transporter 1 Expression in the Kidney
por: Matthews, Jennifer, et al.
Publicado: (2023)

SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging
por: Matthews, Jennifer R., et al.
Publicado: (2020)

Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice
por: Herat, Lakshini Y, et al.
Publicado: (2020)

Sympathetic stimulation with norepinephrine may come at a cost
por: Herat, Lakshini Y., et al.
Publicado: (2019)

Current Knowledge of IL-6 Cytokine Family Members in Acute and Chronic Kidney Disease
por: Magno, Aaron L., et al.
Publicado: (2019)

TNFSF14-Derived Molecules as a Novel Treatment for Obesity and Type 2 Diabetes
por: Agostino, Mark, et al.
Publicado: (2021)

The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice
por: Herat, Lakshini, et al.
Publicado: (2017)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α
por: Magno, Aaron L., et al.
Publicado: (2020)

The Schlager mouse as a model of altered retinal phenotype
por: Herat, Lakshini Y., et al.
Publicado: (2019)

Combined renal and common hepatic artery denervation as a novel approach to reduce cardiometabolic risk: technical approach, feasibility and safety in a pre-clinical model
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2021)

Retinal capillary rarefaction is associated with arterial and kidney damage in hypertension
por: Frost, Shaun, et al.
Publicado: (2021)

Microvascular changes at different stages of chronic kidney disease
por: Kannenkeril, Dennis, et al.
Publicado: (2020)

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation
por: Carnagarin, Revathy, et al.
Publicado: (2021)

Supine blood pressure—A clinically relevant determinant of vascular target organ damage in hypertensive patients
por: Nolde, Janis M., et al.
Publicado: (2020)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
por: Sha, Wenjun, et al.
Publicado: (2020)

The molecular basis for the neutral effect of renal denervation in patients with chronic heart failure not responding to cardiac resynchronisation therapy – a perspective
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2019)

A cautionary note for researchers treating mice with the neurotransmitter norepinephrine
por: Matthews, Vance B., et al.
Publicado: (2018)

SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
por: Podestà, Manuel Alfredo, et al.
Publicado: (2023)

Multi-organ denervation: a novel approach to combat cardiometabolic disease
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2023)

Biomarkers for Diabetic Retinopathy – Could Endothelin 2 Be Part of the Answer?
por: Binz, Nicolette, et al.
Publicado: (2016)

Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
por: Panchapakesan, Usha, et al.
Publicado: (2013)

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
por: Wołos-Kłosowicz, Katarzyna, et al.
Publicado: (2022)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice
por: Weerasekera, Lakshini, et al.
Publicado: (2017)

Retinopathy and Risk of Kidney Disease in Persons With Diabetes
por: Hong, Jingyao, et al.
Publicado: (2021)

Sympathetic Activation in Hypertensive Chronic Kidney Disease – A Stimulus for Cardiac Arrhythmias and Sudden Cardiac Death?
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2020)

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
por: Dai, Zhi-Cheng, et al.
Publicado: (2023)

Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients
por: Pham, Phuong-Thu T., et al.
Publicado: (2022)

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
por: Moura, Filipe A., et al.
Publicado: (2023)

SGLT2 inhibition to address the unmet needs in diabetic nephropathy
por: Barutta, Federica, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
por: Srinivas, Natasha, et al.
Publicado: (2021)

Immunohistochemical Characterization of Connexin43 Expression in a Mouse Model of Diabetic Retinopathy and in Human Donor Retinas
por: Mugisho, Odunayo O., et al.
Publicado: (2017)

Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease
por: Shaffner, James, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t2f87pelrfcdhu98m93fo9vbuu